Green Cross Teams Up With MacroGenics For Bio-better Of Roche's Herceptin

SEOUL - South Korea's Green Cross has signed an agreement with Rockville, Maryland-based MacroGenics to develop and sell the latter's modified anti-breast cancer monoclonal antibody MGAH22 in Korea. MGAH22 is a modified "bio-better" of Roche's oncology agent Herceptin (trastuzumab)